Ovid Therapeutics Inc. Regains Compliance with Nasdaq Listing Rule

On September 11, 2025, Ovid Therapeutics Inc. received a formal notification from The Nasdaq Stock Market LLC confirming that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires listed companies to maintain a minimum bid price of at least $1.00 per share. The notification also stated that the matter is now closed. This development is significant as it ensures the company's continued listing on Nasdaq, which is crucial for maintaining investor confidence and access to capital markets.